Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 14,701–14,800 of 15,747
Self-inhibiting percolation and viral spreading in epithelial tissuePreprint
Xu, X., Nielsen, B. F., & Sneppen, K. (2024) · eLife · doi:10.7554/elife.94056.2
Yu, C., Carvalho, A. F., Thompson, T., Tsai, T., Tseng, P., Hsu, C., Tu, Y., Yang, S., Hsu, T., & Liang, C. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4184790
Lundstrom, K. H. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-89837-9.00014-0
Witczak, P. (2022) · Wydawnictwo Naukowe Instytutu na rzecz Kultury Prawnej Ordo Iuris eBooks · doi:10.37873/oipress.37.43
Glenn, D. A., Hu, Y., Free, M. E., Premkumar, L., Narowski, T. M., Coleman, C., Elmore, S., Collie, M. M., Culton, D. A., Orzechowski, N. M., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1813924 · Cited by 1
Vaccination Worldwide: Strategies, Distribution and ChallengesPreprint
Samal, C., Jakimowicz, K., Dasgupta, K., Vashishtha, A., Francisco, O., Natarajan, A., Nazir, H., Varma, A. S., Dahake, T., Pandey, A. A., et al. (2021) · arXiv (Cornell University) · doi:10.13140/rg.2.2.10460.46726 · Cited by 8
Perceptions and Willingness of Young Citizens for Covid-19 Vaccination in Indonesia
Saputra, M., & Reuwpassa, J. O. (2022) · doi:10.2991/978-2-494069-55-8_7
SARS-Coronavirus-2: The Unexpected Plague
Wilson, V. G. (2025) · Springer eBooks · doi:10.1007/978-3-031-87562-5_13
Nanoparticle-Based Antigen Delivery: Advancing Immunization Strategies against Infectious Pathogens
Patra, S., Pathan, N. S., Karpe, Y. A., & Gajbhiye, V. (2026) · Biomaterials Research · doi:10.34133/bmr.0385
“Further studies revealed no long-term organ damage, and extensive trials involving BNT162b2 and mRNA-1273 showed only transient local and systemic reactions [ 200 , 201 ].”
Thundakattil, A. V., Prabhu, R., Prabhu, G., Barman, M., Mani, M., De, S., Lwin, H., Giribabu, N., & Das, S. (2025) · Scientific Reports · doi:10.1038/s41598-025-07895-6 · Cited by 1
Köber, M., González‐Domínguez, I., Valdospinos, D., Puente‐Massaguer, E., Piqué-Ponti, J., Piña, D., Avilés‐Domínguez, L., Boloix, A., Segura, M. F., Ventosa, N., et al. (2025) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.5c01328
Domma, F., Soraci, L., Paparazzo, E., Amerise, I. L., Aceto, M. A., Cassano, T. S., Bellizzi, D., Cosimo, S. C., Morelli, F., Corsonello, A., et al. (2026) · Viruses · doi:10.3390/v18010109
Placebos, nocebos, and COVID-19: Society, science, and health care during the pandemic
Calabrese, L. H. (2023) · Oxford University Press eBooks · doi:10.1093/med/9780197645444.003.0014
Vita, E., Monaca, F., Mastrantoni, L., Piro, G., Moretti, G., Sparagna, I., Stefani, A., Vitale, A., Trovato, G., Salvatore, M. D., et al. (2025) · Vaccines · doi:10.3390/vaccines13030273
Translation of lipid based formulation for pulmonary drug delivery system: Clinical status
Mohini, K., Shabnam, T., Sharma, R., & Sharma, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-22374-7.00017-7 · Cited by 1
Evolution of our understanding of MS-COVID-19 interactions and concerns for vaccination
Podury, S., Khan, E. I., Tandon, M., et al. (2021) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2021.05.063
Wang, S., Zhang, X., Hu, X., Li, Y., Qiu, L., Zhang, X., Wang, W., (176511), L. W., Li, Y., Chen, Z., et al. (2026) · Scientia Sinica Vitae · doi:10.1360/ssv-2026-0119
Jacob, M., & Guo, E. X. (2021) · medRxiv · doi:10.1101/2021.08.09.21261809
“While vaccines like Moderna and Pfizer-BioNTech mRNA vaccines work remarkably well, with the BNT162b2 mRNA vaccine of Pfizer and BioNTech having a 95% protection [11], there are documented cases of breakthrough infections, which are only increasing with the new Delta variant [12].”
BackgroundKahn, R. J., Villar, S. S., Dean, N. E., & Lipsitch, M. (2024) · Springer eBooks · doi:10.1007/978-3-031-48408-7_32 · Cited by 1
Advances in nano biomaterials for biomedical engineering
Chaniyara, P., Gandhi, M., Maiya, D., & Patel, T. (2026) · International review of cytology · doi:10.1016/bs.ircmb.2026.04.001
Matsunaga, T., Higashidate, Y., Inazawa, N., Ando, S., & Takahashi, M. (2021) · Cureus · doi:10.7759/cureus.19140
“Results of multinational, placebo-controlled, observer-blinded, pivotal efficacy trial reported that individuals aged 16 years or older receiving two-dose regimen the trial vaccine BNT162b2 (mRNA-based, BioNTech/Pfizer) when given 21 days apart conferred 95% protection against COVID-19 with a safety profile similar to…”
BackgroundKaushik, R., Nikita, Lugani, Y., Gupta, S. K., Gururaj, K., Arya, A., & Rishabh (2024) · Research Square · doi:10.21203/rs.3.rs-1098955/v5
“COVID-19 vaccine anaphylaxis: IgE, complement or what else?”Preprint
Cabanillas, B., Akdiş, C. A., & Novak, N. (2020) · doi:10.22541/au.160883060.08977291/v1
(2022) · doi:10.1101/2021.12.29.21268529
“All three vaccines have been shown to elicit antibody- and T cell-mediated antiviral immune responses which confer almost complete protection against infection with the COVID-19 virus in healthy individuals [30-36].”
BackgroundModeling vaccine allocation and equity implications of COVID-19 containment strategiesPreprint
Nakamoto, I., & Zhang, J. (2022) · medRxiv · doi:10.1101/2022.09.05.22279623
Farrelly, C. (2026) · Oxford University Press eBooks · doi:10.1093/9780197830062.003.0011
Sieber‐Schäfer, F., Kromer, A. P. E., Molbay, M., Carneiro, S. P., Jiang, M., Nguyen, A., Müller, J. T., Benito, J. F., & Merkel, O. M. (2026) · ACS Nano Medicine · doi:10.1021/acsnanomed.6c00078 · Cited by 1
Uozumi, R. (2023) · Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics · doi:10.3999/jscpt.54.2_89
Überstandene COVID-19 schützt wohl so gut vor Reinfektion wie Impfung
Rosenbruch, J., & Sorichter, S. (2021) · Pneumo News · doi:10.1007/s15033-021-2705-0
Reinhart, A. M., Tian, Y., & Lilly, A. E. (2025) · Health Communication · doi:10.1080/10410236.2025.2485296
“Vaccination is widely regarded within the scientific community as the most effective means of reducing the severity and spread of COVID-19 (Cromer et al., 2023; Polack et al., 2020).”
Current status and future developments of vaccines for older people in Japan
山口, 泰. (2025) · Nippon Ronen Igakkai Zasshi Japanese Journal of Geriatrics · doi:10.3143/geriatrics.62.356
Translational Nanomedicine and Delivery Tools for Cardiovascular Disease Therapy and Diagnostics
Miller, M. A., & Williams, R. M. (2026) · Advances in experimental medicine and biology · doi:10.1007/978-3-032-22285-5_10
Inizan, C., Courtot, A., Sturmach, C., et al. (2024) · medRxiv · doi:10.1101/2024.04.09.24305559
“However, in Pfizer BNT162b2 efficacy trial, the cohort included only 0.2% Native Hawaiians/other Pacific Islanders 10 , precluding to assess vaccine efficacy in this population.”
BackgroundInfluentialO IMPACTO DA PANDEMIA DO CORONAVÍRUS NA SAÚDE MENTAL DOS PROFISSIONAIS DE SAÚDE
Sarmento, A. M. P., Gomes, A. C. Á., Dornelas, D. H. D. S., Teixeira, F. D. C., Oliveira, J. S. D., Canêdo, J. A., Batista, L. M., Marques, L. A. M., Pereira, R. L., SCHACHT, V., et al. (2021) · doi:10.22533/at.ed.5942102096 · Cited by 2
Efectos adversos a la vacuna Pfizer-BioNTech en personal de un hospital de tercer nivel
Ramírez-Camacho, M. A., Arcos-Díaz, A., Torres-Erazo, D. S., Argáez-Ojeda, K. A., Marín-Alvarado, C. P., & Lara‐Riegos, J. (2024) · Ars Pharmaceutica (Internet) · doi:10.30827/ars.v66i1.31090
Natural Capital Exploration and Coronavirus Disease Spread in 2020
Piao, X. (2022) · Theoretical Economics Letters · doi:10.4236/tel.2022.122022
Mohamed, S. A. A., Elkarim, M. A., & Al-Jaberi, S. A. (2024) · Cureus · doi:10.7759/cureus.75889
“Local reactions such as redness, pain, and swelling at the injection site were the most common encountered local adverse events [14,15].”
Russ, A., Viherlehto, V., Brey, S., Wittmann, S., Irrgang, P., Leicht, N., Cordsmeier, A., Ensser, A., Rieker, R. J., Geppert, C. E., et al. (2026) · PLoS Pathogens · doi:10.1371/journal.ppat.1014167
“[2,3] Although the pandemic subsided with the appearance and successful spread of the Omicron virus variant and its extensive diversification into sublineages in 2021/2022, problems of vaccine strategies targeting solely the S protein became visible during the course of the pandemic.”
Basile, K., Agius, J. E., Fong, W., McPhie, K. A., Fennel, M., Ko, D., Heuston, L., Lam, C., Arnott, A., Chen, S. C.-A., et al. (2025) · Viruses · doi:10.3390/v17091161 · Cited by 1
“These mutations are particularly frequent in the spike (S) glycoprotein, the target for many vaccines and therapeutics [1,2].”
Marcellus, Voss, C. J. D., Li, S., Ateere, A., McShane, H., & Stylianou, E. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1807190 · Cited by 2
Flynn, J., Dinneen, E., O’Riordan, C., Szafran, J., Power, M., Hickey, M., Gargan, S., McCormack, W., Sheils, O. M., Smyth, B., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-7197612/v1
Gül, A., Gül, C., Karakavuk, T., Karakavuk, M., Can, H., Ülbeği-Polat, H., Serhatlı, M., Yazıcı, H., KÖM, Ş., Ekiz, A. T., et al. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119679
COVID-19: Reasons for Guarded Optimism
Snell, N. J. C. (2021) · Pharmaceutical Medicine · doi:10.1007/s40290-021-00381-0
Lipid Nanoparticles at the Crossroads of Chemistry and Medicine: A Tutorial
Rogado, M. T., Wang, A., Zeng, S., Wang, Z., & Burda, C. (2026) · ACS Nanoscience Au · doi:10.1021/acsnanoscienceau.6c00096
Lignitz, S., & Zepp, F. (2021) · Diabetes aktuell · doi:10.1055/a-1645-9479
“[36] Polack FP, Thomas SJ, Kitchin N et al.”
BackgroundTranchito, E. N., Goslawski, A. M., Cabrera, C. I., Rabbani, C. C., Fowler, N., Li, S., Thuener, J. E., Lavertu, P., Rezaee, R. P., Teknos, T. N., et al. (2022) · Encyclopedia · doi:10.3390/encyclopedia2040133 · Cited by 1
Turner, E. J., & Brahams, D. (2021) · Medico-Legal Journal · doi:10.1177/0025817221990520
Challenges of COVID-19 Vaccination in the Context of Transplantation - A Narrative Review
Meshram, H. S., Kute, V. B., Agarwal, S. K., & Sahay, M. (2021) · Indian Journal of Transplantation · doi:10.4103/ijot.ijot_52_21
Foster, D. R., & Sowinski, K. M. (2022) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1613
REVIEW ARTICLE: EPIDEMIOLOGY OF COVID’19
Courage, I., Oghenevwede, O., Gene-Genald, A., et al. (2020) · American Journal of Health Medicine and Nursing Practice · doi:10.47672/ajhmn.635
Cusi, M. G., Giacomo, A. M. D., Anichini, G., Savellini, G. G., Terrosi, C., Gandolfo, C., & Maio, M. (2023) · Viruses · doi:10.3390/v15030614
“Fortunately, owing to a concerted global effort, several highly effective vaccines have been developed at an unprecedented speed [20,21].”
BackgroundParents' Attitudes toward COVID-19 Vaccination: A Study from Two Centers in Istanbul
Saka, S. Ç., Kafi, H. M., Çakın, Z. E., Fırat, C. K., Toprak, A., & Türel, Ö. (2023) · Journal of Pediatric Infectious Diseases · doi:10.1055/s-0042-1760635 · Cited by 1
Wu, J. (2022) · International Journal of Coronaviruses · doi:10.14302/issn.2692-1537.ijcv-22-4117
Long-term clinical outcomes and prognosis
Molinari, L. V., Ricci, F., Gallina, S., Fedorowski, A., & Chahal, C. A. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-14001-3.00012-1
Neurological Complications after COVID-19 Vaccination
Мухсиновна, Х. Х., Rashidova, N., & Salimjonov, J. (2024) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-024-01624-8
(2022) · doi:10.1101/2022.08.02.22278342
“COVID-19 illness from the parental viral strains [6, 7].”
BackgroundBeyond the blood: Tissue-resident immunity shapes SARS-CoV-2 vaccine antibody responsesPreprint
Schröter, J., van Dorp, C. H., Davis‐Porada, J., Teijaro, J. R., Färber, D. L., & Yates, A. J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.23.740375
Evolution of HIV virulence in response to disease-modifying vaccines: A modeling study
Reid, M. C., Mittler, J. E., Murphy, J. T., Stansfield, S. E., Goodreau, S. M., Abernethy, N. F., & Herbeck, J. T. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.08.071
High-tech Drugs Against COVID-19
Moingeon, P. E. (2025) · Springer eBooks · doi:10.1007/978-3-031-91668-7_1
Update 2021: COVID-19 aus Sicht der Infektiologie
Khatamzas, E., & Kroidl, I. (2021) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1449-4964
“Die klinischen Endpunkte sind bei allen Studien Hospitalisierung sowie schwere Erkrankungen [9].”
BackgroundMa, G., Xie, S., Zhao, L., & Kang, J. L. (2026) · Journal of the American Statistical Association · doi:10.1080/01621459.2026.2682540
“Based on this EHR dataset, we aim to develop vaccination policies that improve upon current observed practices and better address the needs of diverse patient populations, including the immunosuppressant groups that were underrepresented in clinical trials (Polack et al., 2020; Risk et al., 2022a).”
YÖNETİM, KAMU SAĞLIĞI VE FİNANS: COVID-19 AŞI KAMPANYALARINI ANLAMAK İÇİN TEORİK BİR ÇERÇEVE
Uçkaç, B. C. (2025) · Akademik Hassasiyetler · doi:10.58884/akademik-hassasiyetler.1660050
吕, 攀., Lou, M., Qiu, Z., Xia, R., Shu, J., & Lu, G. (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2709262
Mandal, D., Saeed, S., Mandal, P., Kaur, K. N., & Ganguly, N. K. (2025) · Discover Public Health · doi:10.1186/s12982-025-00487-9
mRNA Vaccines: Unlocking Potential, Exploring Applications, and Envisioning Future Horizons
Mishra, G., Rathee, S., Garg, M., & Patil, U. K. (2025) · Current Drug Delivery · doi:10.2174/0115672018320938241121075859 · Cited by 1
Outbreak of Deadly Coronavirus (COVID-19) Pandemic: Diagnosis and Management
Tiwari, A., Singh, D., Kumar, D., Chandra, V., Vishvakarma, N. K., Shukla, D., Jha, H., & Singh, R. P. (2024) · Springer eBooks · doi:10.1007/978-981-97-4723-8_15
Rugājs, R., Madelāne, M., Ivanovs, A., & Vīksna, L. (2024) · Proceedings of the Latvian Academy of Sciences Section B Natural Exact and Applied Sciences · doi:10.2478/prolas-2024-0002
Possible COVID-19 Vaccine-associated Diseases
Vahabi, M., & Ghazanfari, T. (2022) · Immunoregulation · doi:10.32598/immunoregulation.5.1.5
Feldmane, S., Mārtinsone, K., & Perepjolkina, V. (2024) · Proceedings of the Latvian Academy of Sciences Section B Natural Exact and Applied Sciences · doi:10.2478/prolas-2024-0010 · Cited by 1
COVID-19 Rapid Guideline - Organisation and Management in Low Resource Countries
Vancheeswaran, R., Barlow, A., Pyae, P. K., O'Neill, A., Vancheeswaran, V., Mitchell, H., Cama, R., & der Watt, M. V. (2021) · The Physician · doi:10.38192/1.7.1.7
Emerging mRNA-based nanomedicines for cancer immunotherapy
Yu, C., Wu, X., Luo, S., Wang, H., Huang, C., Zhang, L., & Zhu, D. (2026) · Chinese Chemical Letters · doi:10.1016/j.cclet.2026.113288
Rajapakse, R. O., & Sharma, A. (2021) · Clinical gastroenterology · doi:10.1007/978-3-030-81780-0_16
Parra, P. N. B., Atanasov, V. A., Meurer, J., Whittle, J., Luo, Q., Zhang, R., & Black, B. S. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3850192
Coronavirus disease (COVID-19) in patients with hematologic malignancy
Gong, I. Y., & Hicks, L. K. (2023) · Canadian Hematology Today · doi:10.58931/cht.2023.2231
Ünal, S., Gürsoy, M., & Pasin, O. (2025) · The Anatolian Journal of General Medical Research · doi:10.4274/anatoljmed.2025.74946
Self-citationBruel, S., Gagneux‐Brunon, A., Charles, R., Gocko, X., & Botelho-Nevers, É. (2022) · La Presse Médicale Open · doi:10.1016/j.lpmope.2022.100024
“Data on phases II/III of the Pfizer/BioNTech vaccine were subsequently disseminated by the FDA and published in the New England Journal of Medicine [13,25], while AstraZeneca / Oxford recently published its aggregated data on phase I/II, II/III and III trials (United Kingdom, Brazil, and South Africa) [14].”
MethodCellular and humoral responses to SARS-CoV-2 vaccination in immunosuppressed patients
(2021) · doi:10.1101/2021.12.03.21267250
“Currently, mass vaccination programmes, utilising regulatory-approved vaccines, remains the best way to prevent viral transmission [3,4], severe disease, death [5,6] and overwhelming the already stretched healthcare services.”
Suria, C., Boscá-Watts, M. M., Navarro, P., Tosca-Cuquerella, J., Antón, R., Sanahuja, A., Revaliente, M., & Mínguez, M. (2022) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2021.06.003
Chang, Y., Hung, K.-H., Su, C., Hsiung, C., Liu, Y., & Yeh, L. (2023) · Research Square · doi:10.21203/rs.3.rs-3631014/v1
Therapeutic Modalities for Coronavirus SARS-CoV-2 (COVID-19)
(2022) · Advances in Hematology and Oncology Research · doi:10.33140/ahor.05.01.06
Zhou, L., Li, M. S., Wen, J., Zhang, C., Xiong, C., Ma, W., Dai, Z., Zhang, X., & Mei, H. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110167
Structure-Guided Vaccine Design
Alam, N., & Higgins, M. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-824465-4.00157-5
Exploratory Factorial Model of Perceived Safety in the COVID-19 Era
Fuentes, J. A. A., Crisanto, G. P., & Lirios, C. G. (2023) · KomunikA · doi:10.32734/komunika.v19i01.10627
AI-driven advancements in vaccine development: From discovery to global deployment
Ali, A. M., Mushtaq, D., Qadri, S., Saman, S., Almuqdadi, H. T. A., Hindi, A. A., Neeraj, Jasim, O. M., Sharma, A., & Qazi, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44430-2.00001-3
Gabrić, P. (2021) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/sjhra
Blinc, A., Buturović‐Ponikvar, J., & Fras, Z. (2022) · Strojniški vestnik – Journal of Mechanical Engineering · doi:10.5545/sv-jme.2022.64
“Vaccines against SARS-CoV-2 have been developed in record time and especially mRNA vaccines have proven to be very safe and effective against the early strains of SARS-CoV-2 [25] and [26].”
BackgroundAs principais vacinas contra COVID-19: cenário brasileiro em 2021
Santos, Â. R. V., Cabral, G. F. C., Costa, J. D. O., Silva, L. T., Campos, L. A. A. L., Batista, L. V., Santos, M. C. C., Weinem, M. C. F., Silva, S. M., & Ribeiro, T. M. (2021) · Editora Pasteur eBooks · doi:10.29327/544022.2-19
Jang, W., Kim, B., Kim, E. S., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1209219/v1
Special Issue “COVID-19: Diagnostic Imaging and Beyond—Part II”
Giraudo, C., & Busch, I. M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11133786
“Especially the rapid development of effective vaccines represented an extraordinary achievement, leading to reduced morbidity and mortality worldwide [3,4].”
BackgroundShort-term side effects of BNT162b2 vaccine in primary care settings in Qatar: a retrospective study
Abdeen, S., Alah, M. A., Zaidan, M., Ibrahim, M. I. M., Abdulmajeed, J., Al-Nuaimi, A. A., & Al‐Kuwari, M. G. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1384327 · Cited by 1
Lyou, H. J., & Lee, H. L. (2023) · Journal of Multiple Sclerosis and Neuroimmunology · doi:10.59578/jmsni.14.2.73
Respuesta inmunitaria anti-SARS-CoV-2: Infección Natural vs. Vacunación
Oropeza, M. J. P., Sanchez, S. R., Fuentes, C. S., Manrique, M. S., Rodríguez, I. V., & Escobar-Guevara, E. E. (2023) · Revista Digital de Postgrado · doi:10.37910/rdp.2023.12.1.e358
Ye, C., Park, J., Chiem, K., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.13.484172
An Update on the Leading COVID-19 Vaccines
Eladely, A. (2021) · The University of Louisville Journal of Respiratory Infections · doi:10.18297/jri/vol5/iss1/2
Babasola, O., Bakheet, M., Naesborg-Nielsen, C., et al. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1819528
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.